SCHEMBL7498474

SCHEMBL7498474

Cc1csc(=N)n1Cc1cnc(Cl)s1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 3/20 0.42
KMT2A Q03164 3/20 0.37
RECQL P46063 1/20 0.37
MAPT P10636 3/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
L3MBTL1 Q9Y468 5/20 0.35
TDP1 Q9NUW8 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
POLB P06746 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7508741 0.74 CHRNA1 (0.55) LMNAGAAMAPTL3MBTL1
SCHEMBL7503621 0.68 CYP11B1 (0.41) LMNAALDH1A1GAAKMT2AMAPT
SCHEMBL7504124 0.67 ERCC5 (0.40) ALDH1A1GAAKMT2AMAPTRAB9A
SCHEMBL1274373 0.66
SCHEMBL633228 0.66 LMNA (0.54) LMNAALDH1A1GAARAB9AL3MBTL1
SCHEMBL21681908 0.63 ALDH1A1 (0.37) LMNAALDH1A1GAAKMT2ARECQL
SCHEMBL17357984 0.62 ALDH1A1 (0.36) LMNAALDH1A1GAAKMT2ARECQL
SCHEMBL155863 0.62
SCHEMBL14492891 0.62 LMNA (0.43) LMNAALDH1A1GAAKMT2ARECQL
SCHEMBL2187967 0.61 CHRNA1 (0.57) LMNAALDH1A1GAAKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028809-A1 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors SUNTORY LIMITED 2002-03-07 US claimed
EP-1176141-A1 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR SUNTORY LIMITED (JP) 2002-01-30 EP claimed
US-20020028809-A1 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors SUNTORY LIMITED 2002-03-07 US disclosed
EP-1176141-A1 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR SUNTORY LIMITED (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028809-A1 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors CHRNA2, CHRNA7, CHRNB2 LMNA 3137/4885ALDH1A1 1878/4885GAA 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.